Understanding the Benefits of SGLT2 Inhibition
Author:
Open Access
- 25 September 2023
- journal article
- editorial
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 8 (9) , 1098-1099
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart FailureJACC, 2022
- Epicardial adipose tissue in contemporary cardiologyNature Reviews Cardiology, 2022
- Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) InhibitorsJACC: Basic To Translational Science, 2020
- The effect of dapagliflozin treatment on epicardial adipose tissue volumeCardiovascular Diabetology, 2018
- Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation abilityCardiovascular Research, 2017